Martin Lisa Thomas Matthew Johnson Anna

Crooks Plains

Hall Matthew Johnson Betty Lee Kenneth

thanks for the video..its quite clear explanation

Lewis Sandra Brown Jose Martinez Joseph

Lewis Elizabeth Perez Betty Jackson Amy

Harris Eric Lee Karen Lopez Angela

Nice video. Can you please try to be a little audible in subsequent videos. Many of your Audience are from third world countries and have to strain their ears to understand what you're saying.

ماهي مدة ضهور نتيجة اختبار IHC؟

The music is annoying!!

Our tissue sample kept slipping off the glass slide. What should we do to prevent it from happening?

Desellation??? BS

Hi Is the first step applicable if the slides are positively charged?

Very informative & nice one

일 똑바로해라 헐박사야? 장난하냐?

Excuse me, i am miss something or u didnt use decloaking chamber? Thank you, best regards

I go to a school named IHC

Ihc

Well illustrated. Thank you Team StJohnsLab. Audio quality could have been bit more distinct.

Very nice explanation.

what's the purpose of demineralised water? mounting chemical used?

Such a lengthy process 😅

Thank you for providing me this video. It will help me in future 😊

Thank you! so helpful

Great sir

i want to kannads

All indian customers please call us for stj products 9704095071. Western chem solutions hyderabad

All indian customers please call us for stj products 9704095071. Western chem solutions hyderabad

Hi prasad garu..This is sreenivas from Hyderabad.we are the distributors for st Johns laboratories. Please call on 9704095971 any required information

I want Telugu

For large proteins (Mr >100 000). Be sure to run your samples in a low-concentration gel, 8% or less. These will be very fragile, so handle carefully. Large proteins will tend to precipitate in the gel, hindering transfer. Adding SDS to a final concentration of 0.1% in the transfer buffer will discourage this. Methanol tends to remove SDS from proteins, so reducing the methanol percentage to 10% or less will also guard against precipitation. www.creative-diagnostics.com/Electrophoresis-Protein-Transfer.htm

Dr. David Rimm is a Professor in the Department of Pathology at the Yale University School of Medicine. He completed an MD-PhD at Johns Hopkins University Medical School followed by a Pathology Residency at Yale and a Cytopathology Fellowship at the Medical College of Virginia. Dr. Rimm is the Director of Translational Pathology and the Director of Yale Pathology Tissue Services. His lab group (15 researchers) focuses on quantitative pathology using the AQUA® technology invented in his lab with projects related to predicting response to therapy in breast and lung cancer and predicting recurrence or metastasis in breast and lung cancer. The technology has also been used in a series of efforts related to biospecimen science. He also has a group working on primary tumor culture using the conditionally reprogrammed cell method. He is a member of a number of correlative science committees for multi-institutional breast cancer clinical trials including SWOG, ALLTO, and TEACH. He also serves on the Molecular Oncology committee for the College of American Pathologists (CAP). He is currently supported by grants from both public and private sources. He is an author of over 280 peer-reviewed papers and 8 patents. He has served on advisory boards for Genentech, Novaritis, BMS, Perkin Elmer, Dako, ACD, Avida and Genoptix. He was a scientific co-founder of HistoRx, a digital pathology company (sold to Genoptix in 2012) and Metamark Genetics, a prognostic determinant company.

After graduating with an honours degree in Biochemistry Dr Hills worked for several years as a Clinical Scientist at St Bartholomew's hospital in London. He was awarded his PhD in 2002 from the faculty of Medicine at Queen Mary University of London. He continued his interest in reproductive science at Imperial College London where he worked as a postdoctoral researcher before joining Middlesex in 2004 as a lecturer. Dr Hills has published many high profile original research articles on various aspects of obstetric pathology including pre-eclampsia, recurrent miscarriage, preterm labour and fetal distress as well as several articles in the area of assisted reproduction. Currently, he is research interests include investigating the role of glycosaminoglycans and proteoglycans on the development of placental pathology and breast cancer. Dr Hills teaches a range of topics in biomedical science including clinical biochemistry, cellular and developmental biology as well as statistical analysis. He is author of around 30 peer-reviewed scientific articles and has refereed manuscripts for a variety of journals in the area of reproduction and endocrinology.

John Mountzouris completed his Ph.D. in Medicinal Chemistry at the University of Texas, with a focus on structural biology, followed by a post-doctorate at the Scripps Research Institute. His industrial career begin with a stint as a bench scientist Pharmingen (later acquired by Becton Dickinson). He then turned to the business side, with work in sales and marketing, business development and communication at Pfizer, Abgent, and Acris Antibodies. Most recently, he has returned as Site Leader at Abgent, following its acquisition by Wuxi, a global CRO company.

Dr Jan Voskuil is Chief Scientific Officer at antibody manufacturer Everest Biotech in Oxfordshire, UK. After specializing in prokaryotic cell biology through his PhD program in Amsterdam, Netherlands, and a postdoc position at Stanford, California, he switched to the science of neurodegenerative diseases at Oxford, UK through postdoc positions at Dunn School of Pathology and at MRC and through a leading position at the Alzheimer drug discovery company Synaptica. He subsequently gained experience in a GLP-regulatory environment in CRO companies both in Oxfordshire and Cambridgeshire, validating assays in Flow Cytometry and ELISA platforms and writing SOPs. His extensive experience with generating and characterizing monoclonal and polyclonal antibodies in combination with accrued knowledge on immunoassays in academic and commercial environments made him the ideal candidate to take charge in putting Everest Biotech on the global map by ever raising the quality and size of its catalogue and by delivery of adequate technical support. As a result, Everest antibodies are currently part of most globally well-known catalogues, and its products are increasingly recognized as useful alternatives to unfit monoclonal antibodies.

Dr Chalmers is a cell biologist based at the University of Bath, UK and he currently leads a team investigating the role of stem cell regulators in prostate cancer. In 2014 he was promoted to a Senior Lectureship. Dr Chalmers have published over 25 peer reviewed papers, been invited to national and international conferences and been awarded major research grants from research councils and charities. He is also the founder of CiteAb, a citation based antibody search engine. The idea of CiteAb was birthed through frustration with using failed commercial antibodies. CiteAb aims to provide a better way for researchers to find antibodies which are suitable for their experiments. CiteAb was spun out of the University of Bath in January 2014 and Dr Chalmers is the currently the Chief Scientific Officer.

Fridtjof Lund-Johansen is an MDPhD who has worked for 30 years with antibodies and flow cytometry. He took his degree at the University of Bergen in Norway. He then did post-docs in California, first at Becton Dickinson in San Jose and then at DNAX instiute of Immunology in Palo Alto. He is now a PI at the Institute of Immunology at Oslo University Hospital where he leads an effort to develop antibody-based proteomics. His technology is called MAP for microsphere affinity proteomics. He will talk about how MAP can be used to test thousands of antibodies in parallel.

Dr. Glerup is Associate Professor at Aarhus University, Denmark and Mayo Clinic, Florida. He earned his PhD in molecular biology at Aarhus University in 2008 and continued as postdoc in neuroscience where after he was appointed group leader in 2012. His laboratory focusses on molecular pathways in cognition and employs a variety of techniques including transgenic animal models, molecular neurobiology, and imaging. The laboratory is particular interested in a family of sorting receptors, sortilins, and their role in regulating neuronal development and function, and further how they contribute to the development of mental disorders. Dr. Glerup is also the founder of the antibody review database pAbmAbs (www.pabmabs.com) that collects information on the use of antibodies in research.

A new article type and platform for the publication of antibody validations. Michael Markie is the Associate Publisher of F1000Research, an open access journal offering immediate, publication, transparent peer review (post‐publication) and full data deposition and sharing. Michael studied Chemical Biology at the University of Leeds, and has since been working in STM publishing for several years. Michael is an open science advocate and is particularly keen on devising new technologies and innovations that can improve the current publishing system and advance the dissemination of tomorrow’s research. For more details about 1st international antibody validation forum please check on www.stjohnslabs.com/ac_cms/blog